article thumbnail

Exploring Flavonoids as Regulators of MMP‐2 and MMP‐9 in Cancer Pathogenesis

Chemical Biology and Drug Design

Studies indicate the potential of plant-derived natural products as anticancer agents through the regulation of MMP activity. Specifically, MMP-2 and MMP-9 have emerged as promising targets in cancer treatment based on their critical roles in cell invasion, angiogenesis, immune evasion, and metastasis.

article thumbnail

Chromone Derivatives as a Novel NOX4 Inhibitor: Design, Synthesis, and Regulation of ROS in Renal Fibroblast

Chemical Biology and Drug Design

A series of chromone derivatives were designed and synthesized. We established a NOX4 overexpression model using the NRK-49F and identified compound 14m as highly active through the assessment of intracellular ROS levels. This investigation positions 14m as a noteworthy NOX4 inhibitor, shedding light on its regulatory role in renal fibroblasts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Streamlining the Generic Drug Supply Chain: Best Practices

Drug Patent Watch

By implementing these strategies, manufacturers, distributors, and regulators can work together to improve efficiency, reduce costs, and increase patient access to affordable medicines. By working together, manufacturers, distributors, and regulators can create a more efficient and patient-centric generic drug supply chain.

article thumbnail

CDMO Selection: The Ultimate Checklist

Drug Patent Watch

In this article, we will delve into the key criteria for selecting a CDMO, highlighting the essential factors to consider and the importance of effective communication and cultural fit. Your Drugs Development Stage The stage of your drug development is a critical factor in selecting a CDMO.

article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

In this article, we will delve into the benefits of working with integrated CDMO services and explore how they can streamline the drug development and manufacturing process. This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers.

article thumbnail

Understanding the Regulatory Environment in Japan for Generic Drug Development

Drug Patent Watch

This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. Pharmaceutical Regulations in Japan 2020. Freyr Solutions.

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Regulators care a lot about controlling the Type 1 error rate of the clinical trial, Smith notes. By proving that their digital twin models can significantly reduce the number of subjects needed in clinical trials – without compromising trial integrity – Unlearn is making a compelling case for the value of AI.